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THE aim of this hypothesis is to provide new insights
into the still unclear mechanisms governing airway
inflammation in cystic fibrosis. Although the genetic
basis  of  cystic  fibrosis  as  well  as  the  molecular
structure of cystic fibrosis transmembrane regulator
(CFTR), the mutated protein which causes the disease,
have been well defined, a clear relationship between
the genetic defect and the pulmonary pathophysiol-
ogy,  especially  chronic  infections  and  neutrophil-
dominated airway inflammation has not been estab-
lished. Cystic  fibrosis is thus a unique pathological
situation in that neutrophils can be depicted as both
an  antiinfectious  and  a  proinflammatory  cell.  In
cystic  fibrosis  there  is  an  emerging  picture  of  an
imbalance  between  these  two  roles  with  both  a
reduction in the antiinfectious efficacy and an aug-
mentation of the proinflammatory functions. Better
knowledge  of  fundamental  defects  in  neutrophil
function in cystic fibrosis as well as a novel cellular
function of CFTR, which will be reviewed, will allow
identification of potentially new clinical targets and
aid  selective  therapeutic  action  aimed  at  counter-
acting  the lethal neutrophil-induced airway inflam-
mation.  The  rationale  for  colchicine  therapy  is  a
significant example of a drug which might act both at
the molecular levels on CFTR expression in epithelial
cells and on neutrophils to mediate antiinflammatory
effects. Preliminary results are presented in this issue
(Med Inflamm 1999; 8: 13–15).
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Genetic basis and pathogenesis of cystic
fibrosis
Cystic fibrosis (CF) is a chronic lung disorder charac-
terized, at an early age, by bacterial deposition in the
airways,  the  production  of  thick,  infected  mucus,
combined  with  an  hypersecretory  state  of  serous
cells1 as  well  as  a  chronic  airway  inflammation
dominated by neutrophils.2 CF is the most common
autosomal recessive genetic disorder in Caucasians. It
is  caused  by  the  mutation  of  the  cystic  fibrosis
transmembrane regulator (CFTR)  gene  which spans
250 kilobases on chromosome 7.3 Over 800 mutations
of CFTR are associated with CF, but the most common
is the deletion of phenylalanine at position 508 of the
1480-residue CFTR protein. CFTR acts as a chloride
channel on the apical surface of epithelial cells, and
responds to increases in intracellular levels of cyclic
AMP.4 The biological perturbations are an increase in
sodium  and  chloride  concentrations  in  secretions,
e.g. in sweat, which is a diagnostic feature, as well as
in pancreatic secretions leading to pancreatic insuffi-
ciency. In the airways, there is an increase in mucus
viscosity, thus impairing mucociliary clearance.5
Chronic bronchial infections in CF
CF is  thus  characterized by  lung  colonization with
different  types  of  bacteria,  ultimately  ending  in
Pseudomonas  aeruginosa colonization resulting  in
tissue destruction by emigrating neutrophils. In addi-
tion, in situ neutrophil decomposition is the major
source of the DNA that renders the sputum viscous
and leads to bronchial obstruction. In the late stage,
the host defence mechanisms directed at clearing the
mucosa  containing  infecting  microorganisms  are
greatly  impaired, and consequently, bacterial patho-
gens are rarely eradicated from the airways even with
aggressive  antimicrobial  treatment,  whether  intra-
venous or delivered directly to the respiratory tract by
aerosol.6 Disease progression is punctuated by acute
episodes of  infection  exacerbating  respiratory tract
disease,  that  ultimately  lead  to  severe  bronchial
damage, respiratory insufficiency, and death.7 Pulmo-
nary infections are the main cause of morbidity and
mortality.
Most  clinical  studies  designed  to  unravel  the
mechanisms causing CF patients to be highly suscepti-
ble to infections have focused on proteases, and on
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current explanation for the persistence of P. aerugi-
nosa in  the  respiratory  tract  is  the  emergence  of
mucoid strains specific of CF, which are resistant to
phagocytosis.8 However,  more  recent  data  suggest
that CFTR itself may be a major receptor for binding
and internalization of P. aeruginosa and that CFTR-
mediated  ingestion  of  P.  aeruginosa is  critical  for
early and effective clearance from the lung.9
Inflammation in CF: a key role for
neutrophils
The  polymorphonuclear  neutrophils  are  also  con-
sidered  to  be  responsible  for  the  early  onset  and
promotion of  the  inflammatory  process  in  CF. The
vicious cycle of mucosal infection and lung inflamma-
tion begins within the first year of a CF patient’s life.
The  typical  pathophysiologic  feature  of  CF  is  sig-
nificant  ongoing  infection  and airway inflammation
with  clinically  mild  lung  disease.10 Several  studies
investigating  the  complex  relationships  between
infection and inflammation in CF support the concept
that the host inflammatory response is not necessarily
proportional  to  the  burden  of  pathogens  in  the
respiratory  tract,  although  these  pathogens  may
provide the primary stimulus  for  such responses.11
The  mechanisms  leading  to  neutrophil-dominated
inflammation in CF patients as well as the relation-
ships with CFTR mutations remain largely unknown,
and still less is known about the functional character-
istics  of  neutrophils  in  CF.  However,  it  becomes
increasingly apparent that the clinical evolution of CF
patients is more closely related to the state of airway
inflammation. The airway inflammation typical of CF
thus  relies  on  the  paradox  of  an  exacerbation  of
neutrophil-mediated tissue damage and concomitant
persistence of inflammation.
Neutrophils mediate host defence and tissue dam-
age  by  two  pathways:  firstly,  the  NADPH  oxidase
system can produce toxic oxygen metabolites such as
superoxide  anion  and  hydrogen  peroxide  (H2O2),
while myeloperoxidase, an enzyme located in azur-
ophil granules, catalyses the formation of chlorinated
oxidants from H2O2 and chloride, thus giving rise to
hypochlorous acid (HOCl) and chloramines, the so-
called  long-lived  oxidants;12 secondly,  non-oxygen-
dependent  mechanisms,  which  involve  preformed
proteins (proteinases and antibiotic proteins) mainly
stored  in  azurophil  granules.13 Although  the  two
mechanisms can function  independently, synergy is
needed  for  a  fully  bactericidal  and  destructive
response.
High  concentrations of  neutrophil-derived media-
tors are found in airways, in particular inflammatory
cytokines such as IL-814 and TNF-a ; metalloproteases
such as gelatinase; serine proteases including elastase,
cathepsin G15,16 and as we recently reported, protei-
nase 3,17 with a clear imbalance between proteinases
and  antiproteinases;18 and  the  so-called  antibiotic
peptides or defensins. It has also been shown that
defensin antibiotic activity might be decreased in CF
lung because of the modification in ionic concentra-
tions of the bronchial secretions.19 Most interestingly,
we  have  shown  that  chlorinated  oxidants  were
present  at  very  high  levels  in  bronchial  secretions
from CF patients, thus suggesting that they might play
a  modulatory  role  in  CF  airway  inflammation  in
CF.20
Underlying mechanisms of airway
inflammation: hypothesis of a genetic
defect in CF neutrophils
Several groups are beginning to characterize the role
of mutant CFTR in the inflammatory process. Atten-
tion has recently been focused on a possible disrup-
tion in the autocrine control of cytokine secretion by
epithelial cells characterized by a decrease in inhibi-
tory cytokines such as IL-10 and a dramatic increase in
proinflammatory cytokines such as IL-6, TNF-a and
the  strong  neutrophil  chemotactic  cytokine  IL-8.21
Activation of NFkB and IL-8 transcription have been
reported  in  epithelial  cells  with  CFTR  mutations
following exposure to Pseudomonas ligands.22 These
disturbances  in  cytokine  regulation  which  can  be
observed  in  the  absence  of  detectable  infection
certainly  contribute  to  amplify  and  perpetuate  the
inflammatory process. However, it is still  unknown
whether cytokine dysregulation could by itself trigger
the initial  inflammatory process and the very early
migration of the neutrophils into the airways.
Among the other phagocyte derived mediators, a
disturbance in nitric oxide production could also be
mentioned.  Indeed,  Kelley  et  al.23 have  recently
reported that the inducible  isoform of nitric oxide
synthase  (iNOS)  is  constitutively  expressed  in  the
airway epithelia of non-CF mouse and human tissues
but essentially absent in the epithelium of CF airways
and suggested that the absence of continuous nitric
oxide production in epithelial cells of CF airways may
play  a  role  in  two  CF-associated  characteristics:
hyperabsorption  of  sodium  and  susceptibility  to
bacterial infections.
Another aspect of research on the CF inflammatory
process is based on the investigation of neutrophil
functions  in  CF.  Investigation  of  CF  heterozygotes
could provide an alternative to studying the influence
of  the  CFTR  defect  in  various  cellular  systems.  CF
heterozygotes  carry  both  a  normal  and  a  mutated
allele  of  the  CFTR  but  are  free  from  the  clinical
problems  associated  with  CF.  However,  previous
studies have stressed on  some  physiological abnor-
malities in intestinal and airway epithelium CF hetero-
zygotes.24–27 A  reduced  sweat  production  by  the
secretory  cell  in  response  to  b -adrenergic  but  not
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it has also been proposed that heterozygosity of the
CFTR allele has been selected in certain populations
because it protects against typhoid.28
With regard to neutrophil functions, only few data
on  CF  heterozygotes  are  available.  Although  the
expression  of  CFTR  in  cell  types  of  non-epithelial
origin  and  in  blood  cells  such  as  lymphocytes  has
been  described,  the  presence  of  CFTR  mRNA  in
mature neutrophils has been reported only  once.29
We were unable to detect CFTR protein in neutrophil
membranes  using  Western  blot  analysis  but  the
functional  analysis  of  neutrophils  from  CF  hetero-
zygotes  revealed  disturbed  neutrophil  functions.
Indeed,  our  data  showing  that  myeloperoxidase-
dependent  oxygenation  activities  are  significantly
higher  not  only  in  CF  homozygotes  but  also  in
heterozygote parents of CF patients provided strong
evidence  for  a  genetic  component  to  altered  neu-
trophil  function  in  CF.30 Interestingly,  this  hyper-
production of  intracellular  myeloperoxidase-derived
oxidants  could  be  normalized by  inhibition  of  the
Na+/H+ exchange  system  using  amiloride  or  EIPA,
which are pharmacological blockers, as well as in a
chloline buffer which prevents the exchange system
from working. The Na+/H+ exchange system partici-
pates in phagocytosis and subsequent bacterial killing
by  compensating for the H+ load generated by  the
respiratory burst and thus regulating intracellular pH,
as  well  as  by  the  volume  increase  associated with
neutrophil migration.31,32 A disturbance in this latter
function  might  be  of  relevance in  the  mechanisms
leading  to  excessive  neutrophil  influx  into  the  air-
ways. In addition, a recent study has pointed out a
decrease in the shedding of L-selectin in stimulated CF
neutrophils which was not observed in either stable
or  acutely  infected  non-CF  bronchiectasis  patients,
thus  suggesting  disturbed  control  of  the  migration
process in CF neutrophils.33
Taken together, these data led us to suggest that CF
neutrophils show a modification of intracellular pH
regulation  which  may  play  a  role  in  the  increased
intracellular myeloperoxidase enzymatic activity. An
alternative  hypothesis  might  be  a  decrease  in  the
concentration  of  intracellular  antioxidants  such  as
glutathione which, as we previously demonstrated, is
a major scavenger of chloramines.34
Novel functions for CFTR: relationships
with neutrophil function and rationale for
novel therapy
Several working hypotheses indicate that CFTR could
be a multifunctional protein involved in controlling
ion channels or ion exchanges in the cell other than
Cl–. Most interestingly, CFTR is a member of the ‘ATP-
binding cassette’ (ABC) family of membrane transport
proteins together with the P-glycoprotein associated
with  multidrug  resistance  (MDR)  protein  and  the
multidrug  resistance-associated  protein  (MRP).35 It
has been recently demonstrated that CFTR, like other
ABC proteins, is directly involved in intracellular pH
regulation  since its overexpression in  NIH3T3 cells
decreases intracellular pH.36 Defective acidification of
intracellular organelles has also been shown in nasal
polyp cells isolated from CF children37 but was not
verified by recent studies of Golgi pH in cells from
CFTR null mice.38 Moreover, CFTR appears also to be
a glutathione transporter, a function that is shared by
other ABC proteins.39
Although  we  do  not  have  evidence  whether  a
disturbance in  Na+/H+ antiport in  neutrophils  from
CF homozygotes or heterozygotes is attributable to a
defect  in  CFTR  function,  our  findings  showing  an
increase in MPO-dependent oxidant generation might
also be discussed in the light of the novel functions of
CFTR. In this setting, it could be speculated that the
disturbance in intracellular pH regulation and/or the
defect  in  intracellular  glutathione  concentration
might be attributable to CFTR mutation in CF.
Antiinflammatory approaches and clinical
follow-up of the CF patient: the
neutrophils as the major target
As  CF  involves  chronic  active  inflammation  and
recurrent infections ultimately resulting in inflamma-
tion, clinical management of CF presents a paradox
combining  antibiotherapy  and  antiinflammatory
drugs.
Within  the  past  20  years,  vigorous  antibiotic
therapy, clearance of mucus and nutritional repletion
have been the pillars of conventional CF therapy.6,7
Prospects for effective gene therapy of the respiratory
effects of CF are improving slowly and attention has
been  focused  on  complementary  approaches  to
counteract the symptoms of CF. Several studies have
identified the host inflammatory response as a poten-
tial target for therapy to delay the progression of lung
function  impairment  in  CF  patients.  However,  the
diagnosis  of  pulmonary  exacerbation  is  rendered
difficult in that many CF children do not present with
fever and leukocytosis, and thus, the diagnosis of an
acute  exacerbation  must  be  made  on  a  subjective
basis. In addition, evaluation of the airway inflamma-
tory process is hampered by the fact that, to date, no
clinical tests provide a reliable index of the in situ
pulmonary inflammatory state without invasive tests.
We have recently shown that neutrophil myeloperox-
idase activity correlates with  the inflammatory and
the  infectious  state  of  very  young  CF  patients  in
whom  functional  pulmonary  tests  cannot  be  per-
formed.40 Most  interestingly,  measurement  of  this
inflammatory  index  has  proven  to  be  of  value  in
evaluating the efficacy  of antibiotherapy.  Since less
than a millilitre of blood is required for this analysis,
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to  assess  the  efficacy  of  future  antiinflammatory
therapy.
A study of the non-steroidal antiinflammatory agent
ibuprofen demonstrated its effectiveness in slowing
the progression of lung disease (evaluated by pulmo-
nary-function testing), in slowing the decline of the
percentage of ideal body weight, and in decreasing
the number of hospital admissions during the time of
treatment.41
Antiproteinase therapy has also been proposed and
aerosolization of a 1-antitrypsin or secretory leukopro-
teinase  inhibitor  (SLPI)  have  proven  to  exert  a
beneficial effect on pulmonary function.42–44
A different starting point for clinical research in CF
treatment led  to the proposal  that amiloride  could
improve  CF  clinical  status.  The  administration  of
amiloride aerosols to CF patients is based on its Na+
channel blocking properties at the level of the airway
epithelia. Amiloride treatment enhances water secre-
tion  from  the  cells,  increases  mucus  hydration,
improves mucociliary clearance and delays decline in
lung  function.  It  is  tempting  to  speculate  that the
beneficial  effect  of  amiloride  might  be  due  to  its
corrective  effect  on  MPO-dependent  oxidant
hyperproduction.45
More  recently,  colchicine  has  been  proposed  as
antiinflammatory therapy in CF. The rationale for this
proposal relies on the initial clinical observation that
chemotherapy  performed  on  a  CF  patient  had  a
clearly beneficial effect on the symptoms of CF.46 The
current  hypothesis  of  this  effect  is  that  cancer
chemotherapy might induce overexpression of some
ABC  proteins  such  as  MDR  and  MRP  which  might
functionally complement CFTR. As a corollary, it can
be suggested that another ABC protein inducer, less
toxic than  an  antitumour drug,  might  complement
CFTR.  Colchicine,  which  is  both  an  ABC  protein
inducer  and  an  antiinflammatory  agent  with  direct
effects on neutrophils, has thus been proposed as a
good candidate.47
Conclusion
Neutrophils play a dual role in CF, an antiinfectious
role  in  fighting  pathogens,  and  a  proinflammatory
role, in releasing its deleterious mediators. It has been
repeatedly demonstrated that the clinical outcome of
patients  is  directly  related  to  the  management  of
inflammation. The  promise  of  a  new  approach  to
treatment  depends  on  preserving  airway  epithelial
integrity, which in turn  is linked to controlling the
intensity of the inflammatory response.
Nonetheless, for the clinical management of CF it is
extremely important both to investigate the causes of
recruitment of  neutrophils, and to manage  chronic
airway  inflammation.  Better  knowledge  of  funda-
mental defects in neutrophil function in CF will allow
identification of potential new clinical targets and aid
selective therapeutic action aimed  at counteracting
the lethal neutrophil-induced airway inflammation. It
might possible that, instead of being simply one actor
in  the  host  defence  against  infectious  agents,  neu-
trophils should be  considered as genetically  predis-
posed  to  exacerbated  inflammatory  response. This
exciting new area of constitutive disturbance in CF
neutrophils is currently under study in our laboratory.
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